Cite
Damm M, Efremov L, Birnbach B, et al. Efficacy and Safety of Neoadjuvant Gemcitabine Plus Nab-Paclitaxel in Borderline Resectable and Locally Advanced Pancreatic Cancer-A Systematic Review and Meta-Analysis. Cancers (Basel). 2021;13(17)doi: 10.3390/cancers13174326.
Damm, M., Efremov, L., Birnbach, B., Terrero, G., Kleeff, J., Mikolajczyk, R., Rosendahl, J., Michl, P., & Krug, S. (2021). Efficacy and Safety of Neoadjuvant Gemcitabine Plus Nab-Paclitaxel in Borderline Resectable and Locally Advanced Pancreatic Cancer-A Systematic Review and Meta-Analysis. Cancers, 13(17), . https://doi.org/10.3390/cancers13174326
Damm, Marko, et al. "Efficacy and Safety of Neoadjuvant Gemcitabine Plus Nab-Paclitaxel in Borderline Resectable and Locally Advanced Pancreatic Cancer-A Systematic Review and Meta-Analysis." Cancers vol. 13,17 (2021). doi: https://doi.org/10.3390/cancers13174326
Damm M, Efremov L, Birnbach B, Terrero G, Kleeff J, Mikolajczyk R, Rosendahl J, Michl P, Krug S. Efficacy and Safety of Neoadjuvant Gemcitabine Plus Nab-Paclitaxel in Borderline Resectable and Locally Advanced Pancreatic Cancer-A Systematic Review and Meta-Analysis. Cancers (Basel). 2021 Aug 27;13(17). doi: 10.3390/cancers13174326. PMID: 34503138; PMCID: PMC8430874.
Copy
Download .nbib